- Home
- NEOV vs TARA Comparison
NEOV vs TARA Comparison
Compare NEOV & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- TARA
- Stock Information
- Founded
- NEOV 2018
- TARA N/A
- Country
- NEOV United States
- TARA United States
- Employees
- NEOV N/A
- TARA N/A
- Industry
- NEOV Industrial Machinery/Components
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEOV Miscellaneous
- TARA Health Care
- Exchange
- NEOV Nasdaq
- TARA Nasdaq
- Market Cap
- NEOV 143.8M
- TARA 165.5M
- IPO Year
- NEOV N/A
- TARA N/A
- Fundamental
- Price
- NEOV $4.26
- TARA $4.28
- Analyst Decision
- NEOV Hold
- TARA Strong Buy
- Analyst Count
- NEOV 1
- TARA 6
- Target Price
- NEOV N/A
- TARA $19.80
- AVG Volume (30 Days)
- NEOV 370.5K
- TARA 380.8K
- Earning Date
- NEOV 11-10-2025
- TARA 11-03-2025
- Dividend Yield
- NEOV N/A
- TARA N/A
- EPS Growth
- NEOV N/A
- TARA N/A
- EPS
- NEOV N/A
- TARA N/A
- Revenue
- NEOV $8,426,835.00
- TARA N/A
- Revenue This Year
- NEOV $91.25
- TARA N/A
- Revenue Next Year
- NEOV $30.38
- TARA N/A
- P/E Ratio
- NEOV N/A
- TARA N/A
- Revenue Growth
- NEOV 218.59
- TARA N/A
- 52 Week Low
- NEOV $1.80
- TARA $2.21
- 52 Week High
- NEOV $6.19
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- NEOV 46.91
- TARA 35.78
- Support Level
- NEOV $3.92
- TARA $4.96
- Resistance Level
- NEOV $4.60
- TARA $5.31
- Average True Range (ATR)
- NEOV 0.39
- TARA 0.29
- MACD
- NEOV -0.01
- TARA -0.18
- Stochastic Oscillator
- NEOV 55.84
- TARA 11.62
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).